title: The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease.
abstract: Liver fatty acid binding protein (FABP1) prevents lipotoxicity of free fatty acids and regulates fatty acid trafficking and partition. Our objective is to investigate the transcription factors controlling the human FABP1 gene and their regulation in nonalcoholic fatty liver disease (NAFLD). Adenovirus-mediated expression of multiple transcription factors in HepG2 cells and cultured human hepatocytes demonstrated that FOXA1 and PPARα are among the most effective activators of human FABP1, whereas C/EBPα is a major dominant repressor. Moreover, FOXA1 and PPARα induced re-distribution of FABP1 protein and increased cytoplasmic expression. Reporter assays demonstrated that the major basal activity of the human FABP1 promoter locates between -96 and -229bp, where C/EBPα binds to a composite DR1-C/EBP element. Mutation of this element at -123bp diminished basal reporter activity, abolished repression by C/EBPα and reduced transactivation by HNF4α. Moreover, HNF4α gene silencing by shRNA in HepG2 cells caused a significant down-regulation of FABP1 mRNA expression. FOXA1 activated the FABP1 promoter through binding to a cluster of elements between -229 and -592bp, whereas PPARα operated through a conserved proximal element at -59bp. Finally, FABP1, FOXA1 and PPARα were concomitantly repressed in animal models of NAFLD and in human nonalcoholic fatty livers, whereas C/EBPα was induced or did not change. We conclude that human FABP1 has a complex mechanism of regulation where C/EBPα displaces HNF4α and hampers activation by FOXA1 and PPARα. Alteration of expression of these transcription factors in NAFLD leads to FABP1 gen repression and could exacerbate lipotoxicity and disease progression.
authors: Experimental Hepatology Unit, IIS Hospital La Fe, Valencia, Spain.
authors: Carla
authors: C
authors: Guzmán
authors: Marta
authors: M
authors: Benet
authors: Sandra
authors: S
authors: Pisonero-Vaquero
authors: Marta
authors: M
authors: Moya
authors: M Victoria
authors: MV
authors: García-Mediavilla
authors: M Luz
authors: ML
authors: Martínez-Chantar
authors: Javier
authors: J
authors: González-Gallego
authors: José Vicente
authors: JV
authors: Castell
authors: Sonia
authors: S
authors: Sánchez-Campos
authors: Ramiro
authors: R
authors: Jover
mesh_terms: D000818:Animals; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000235:genetics / Q000378:metabolism*; D002478:Cells, Cultured; D050556:Fatty Acid-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D005234:Fatty Liver / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D056945:Hep G2 Cells; D051541:Hepatocyte Nuclear Factor 3-alpha / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D065626:Non-alcoholic Fatty Liver Disease; D047493:PPAR alpha / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding
chemical_list: D022763:CCAAT-Enhancer-Binding Protein-alpha; C493319:FABP1 protein, human; D050556:Fatty Acid-Binding Proteins; D051541:Hepatocyte Nuclear Factor 3-alpha; D047493:PPAR alpha